MeaslesNCT04013516
Measles Vaccination Cash Incentives Experimental Evidence From Nigeria
A study testing Cash Incentive and Call in people with Measles, run by IDinsight at 1 site in Nigeria.
Trial summary
IDinsight is conducting a randomized controlled trial to assess the impact of various sized cash incentives for caretakers of infants that require a 9-month measles vaccination on the completion rate for the vaccine in Nigeria. Read more about this study
- Who is it for?
- Ages 9 months and olderHealthy volunteers can take part
- Conditions the study is for
- Measles
- What is being tested?
- Cash Incentive and Call
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,088 participants
- Where
- 1 siteNigeria
- Study dates
- 12 May 2017to 11 Sep 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 months and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Caregiver and infant registered with the New Incentives program
- The infant was nine months or older at the start of the study (note there was no upper age limit as New Incentives only began enrolling infants in October 2016)
- Infant had received at least one previous conditional cash transfer for immunization at an All Babies are Equal Initiative clinic,
- Infant had received their Penta-3 vaccine.
- The caregiver had provided a phone number (either a personal number or a number of someone who can reach them) during registration.
Who cannot join
- Infant had already received a measles vaccine
Trial locations and contacts
1 site in 1 country.
Nigeria1 site
All Babies are Equal Initiative (New Incentives)
Abuja, Federal Capital Territory
About this study
IDinsight is conducting a randomized controlled trial to assess the impact of various sized cash incentives for caretakers of infants that require a 9-month measles vaccination on the completion rate for the vaccine in Nigeria. The purpose of the experiment is to help New Incentives (NI) determine the optimal size of the incentive as they scale to the North West region of Nigeria.
- Conditions
- Measles
- Being tested
- Cash Incentive, Call
- Keywords
- Immunization, Incentives
- Medical subject headings
- Measles
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cash IncentiveBehavioural
During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.
CallBehavioural
A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
| Study group | Role | What they receive |
|---|---|---|
| Pure Control | No intervention | Respondents received New Incentives' normal program. |
| Reminder Call | Placebo comparator | Respondents received a call from a New Incentives' staff member similar to the treatment arms, but weren't offered additional incentives. Receives: Behavioral: Call |
| Small Additional Incentive | Experimental | Respondents were told they would receive 1000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization. Receives: Behavioral: Cash Incentive; Behavioral: Call |
| Large Additional Incentive | Experimental | Respondents were told they would receive 3000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization. Receives: Behavioral: Cash Incentive; Behavioral: Call |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measles Vaccination Coverage Rate
The outcome of interest is the measles coverage rate among the eligible randomized infants. Coverage is measured using the measles vaccination information recorded on the child's health card. The child health card information was immediately entered into the New Incentives' database by their field staff when they disbursed the cash incentives at program clinics. Information from the New Incentives' database was used for the analysis.
Measured: We assessed whether eligible infants received measles vaccination at any time during the 4 month study period. Children were a minimum of 9 months at the beginning of the study and a maximum of 7 years at the end of the study.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2019
- Study start12 May 2017
- Primary completion11 Sep 2017
- Study completion11 Sep 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MeaslesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants randomly assigned to different incentive amounts (treatment arms), a pure control arm, and a placebo arm which consisted of a phone call without an additional incentive.
- Masking
- None (open label)
- Enrolment
- 1,088 participants (actual)
Sponsor and investigators
- Lead sponsor
- IDinsight
- Sponsor type
- University, hospital or other
- Collaborators
- GiveWell
- Responsible party
- Sponsor
- Investigators
- Alison Connor, Principal investigator, IDinsight
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04013516
- Sponsor's protocol ID
- 004
- Status last verified
- Jul 2019
- First submitted
- 27 Jun 2019
- Last updated
- 9 Jul 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Include anonymized data and study protocol as supplementary materials for the published article.
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Measles Vaccination Cash Incentives Experimental Evidence From Nigeria
- ClinicalTrials.gov ID
- NCT04013516
- Acronym / sponsor ID
- 004
- Conditions
- Measles
- Keywords
- Immunization, Incentives
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,088 participants (actual)
- Lead sponsor
- IDinsightUniversity, hospital or other
- Collaborators
- GiveWell
- Study start
- 12 May 2017 (actual)
- Primary completion
- 11 Sep 2017 (actual)
- Study completion
- 11 Sep 2017 (actual)
- First posted
- 9 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
IDinsight is conducting a randomized controlled trial to assess the impact of various sized cash incentives for caretakers of infants that require a 9-month measles vaccination on the completion rate for the vaccine in Nigeria. The purpose of the experiment is to help New Incentives (NI) determine the optimal size of the incentive as they scale to the North West region of Nigeria.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- Participants randomly assigned to different incentive amounts (treatment arms), a pure control arm, and a placebo arm which consisted of a phone call without an additional incentive.
| Arm | Type | Receives |
|---|---|---|
| Pure Control | No intervention | –Respondents received New Incentives' normal program. |
| Reminder Call | Placebo comparator | Behavioral: CallRespondents received a call from a New Incentives' staff member similar to the treatment arms, but weren't offered additional incentives. |
| Small Additional Incentive | Experimental | Behavioral: Cash Incentive, Behavioral: CallRespondents were told they would receive 1000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization. |
| Large Additional Incentive | Experimental | Behavioral: Cash Incentive, Behavioral: CallRespondents were told they would receive 3000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization. |
Who may qualify
- Ages
- 9 months and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Caregiver and infant registered with the New Incentives program
- The infant was nine months or older at the start of the study (note there was no upper age limit as New Incentives only began enrolling infants in October 2016)
- Infant had received at least one previous conditional cash transfer for immunization at an All Babies are Equal Initiative clinic,
- Infant had received their Penta-3 vaccine.
- The caregiver had provided a phone number (either a personal number or a number of someone who can reach them) during registration.
Key exclusion criteria (1 listed)
- Infant had already received a measles vaccine
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cash IncentiveDuring the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination. | Behavioural | Large Additional Incentive, Small Additional Incentive |
| CallA New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver). | Behavioural | Large Additional Incentive, Reminder Call, Small Additional Incentive |
Primary outcome
Measles Vaccination Coverage Rate
Time frame: We assessed whether eligible infants received measles vaccination at any time during the 4 month study period. Children were a minimum of 9 months at the beginning of the study and a maximum of 7 years at the end of the study.
The outcome of interest is the measles coverage rate among the eligible randomized infants. Coverage is measured using the measles vaccination information recorded on the child's health card. The child health card information was immediately entered into the New Incentives' database by their field staff when they disbursed the cash incentives at program clinics. Information from the New Incentives' database was used for the analysis.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2019.
- Individual participant dataSharing planned: Yes. Include anonymized data and study protocol as supplementary materials for the published article.
Related trials for Measles
Recruiting
The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
Iron Deficiencies
RecruitingPhase 4
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients
Heart Transplant Infection Prevention
Not yet recruitingPhase 3
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
Measles, Mumps
RecruitingPhase 3
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
RecruitingObservational study
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Dengue, Chikungunya
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alison Connor principal investigator
IDinsight
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cash Incentive and Call in people with Measles, run by IDinsight at 1 site in Nigeria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Nigeria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measles Vaccination Coverage Rate (time frame: We assessed whether eligible infants received measles vaccination at any time during the 4 month study period. Children were a minimum of 9 months at the beginning of the study and a maximum of 7 years at the end of the study.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2019; AzTrials last refreshed its copy on 8 Nov 2026.